Kairos Pharma Quote - KAPA

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.41

Bid

Offer

Volume

171,590

1.3606 Day's Range 1.52

0.851 52 Week Range 4.00

Market Cap

18.114M

Previous Close

1.36

Open

1.52

Last Trade

1.38

Last Trade Time

Financial Volume

US$ 247,374

VWAP

1.4417

Average Volume (3m)

2,618,692

Shares Outstanding

12,846,785

Dividend Yield

PE Ratio

-10.21

Earnings Per Share (EPS)

-0.14

Revenue

Net Profit

-1.81M

Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, bre... Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate into our company Enviros advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

kairospharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Kairos Pharma Ltd is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker KAPA. The last closing price for Kairos Pharma was US$1.36. Over the last year, Kairos Pharma shares have traded in a share price range of US$ 0.851 to US$ 4.00.

Kairos Pharma currently has 12,846,785 shares in issue. The market capitalisation of Kairos Pharma is US$17.47 million. Kairos Pharma has a price to earnings ratio (PE ratio) of -10.21.

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. Kairos Pharma Ltd. (NYSE...

Form DEF 14C - Other definitive information statements

Form 8-K - Current report

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form PRE 14C - Other preliminary information statements

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form D - Notice of Exempt Offering of Securities

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.17	-10.7594936709	1.58	1.58	1.3	200128	1.39234541	CS
4	-0.08	-5.36912751678	1.49	2.08	1.3	1146876	1.66386626	CS
12	-0.05	-3.42465753425	1.46	3.25	0.851	2618692	2.02613504	CS
26	-2.59	-64.75	4	4	0.851	1574619	2.03260206	CS
52	-2.59	-64.75	4	4	0.851	1574619	2.03260206	CS
156	-2.59	-64.75	4	4	0.851	1574619	2.03260206	CS
260	-2.59	-64.75	4	4	0.851	1574619	2.03260206	CS

KAPA - Frequently Asked Questions (FAQ)

What is the current Kairos Pharma share price?

The current share price of Kairos Pharma is US$ 1.41

How many Kairos Pharma shares are in issue?

Kairos Pharma has 12,846,785 shares in issue

What is the market cap of Kairos Pharma?

The market capitalisation of Kairos Pharma is USD 17.47M

What is the 1 year trading range for Kairos Pharma share price?

Kairos Pharma has traded in the range of US$ 0.851 to US$ 4.00 during the past year

What is the PE ratio of Kairos Pharma?

The price to earnings ratio of Kairos Pharma is -10.21

What is the reporting currency for Kairos Pharma?

Kairos Pharma reports financial results in USD

What is the latest annual profit for Kairos Pharma?

The latest annual profit of Kairos Pharma is USD -1.81M

What is the registered address of Kairos Pharma?

The registered address for Kairos Pharma is 108 W. 13TH STREET SUITE 100, WILMINGTON, DELAWARE, 19801

What is the Kairos Pharma website address?

The website address for Kairos Pharma is kairospharma.com

Which industry sector does Kairos Pharma operate in?

Kairos Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LFAWLife X 2060 Longevity Income ETF	169.97 (911.53%)	314
LFAZLife X 2062 Longevity Income ETF	174.252 (900.00%)	3
LIAWLife X 2062 Inflation Protected Longevity Income ETF	254.313 (900.00%)	8
LFAXLife X 2061 Longevity Income ETF	171.334 (900.00%)	2
LIAVLife X 2061 Inflation Protected Longevity Income ETF	247.646 (900.00%)	13
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 2.86 (-11.18%)	49.86M
MPUMega Matrix Inc	US$ 0.965 (-10.65%)	132.87k
CLDICalidi Biotherapeutics Inc	US$ 1.35 (-10.00%)	1.54M
EFSH1847 Holdings LLC	US$ 0.1704 (-8.88%)	3.4M
AEONAEON Biopharma Inc	US$ 0.124 (-8.82%)	3.69M
DNNDenison Mines Corp	US$ 1.745 (-0.85%)	63.86M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 28.47 (3.38%)	61M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 2.86 (-11.18%)	49.86M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 5.625 (-3.02%)	46.88M
SPYSPDR S&P 500	US$ 609.73 (1.06%)	41.01M